Engineered virus is effective against triple negative breast cancer cells

Scientists have discovered a potential cure for one of the most aggressive and least treatable forms of breast cancer called "triple negative breast cancer." In laboratory experiments involving human cancer cells, scientists used a virus similar to the one that helped eradicate smallpox to coax cancer cells to produce a protein which makes them susceptible to radioactive iodine. This discovery was published in the February 2014 issue of The FASEB Journal. Please note that human clinical trials are necessary before any definitive claims of a cure can be made and treatments can be made available.

"We hope that the recent advances in virology, genetic engineering and targeted radiotherapy will soon translate into an entire class of novel oncolytic, virotherapies for the treatment of deadly cancers," said Yuman Fong, M.D., a researcher involved in the work from the Department of Surgery at Memorial Sloan-Kettering Cancer Center in New York, NY.

To make this discovery, Fong and colleagues successfully infected and killed TNBC cells using a vaccinia virus. In addition, the researchers were also able to use the virus to cause infected cancer cells produce a called hNIS that normally is used to concentrate iodine in thyroid cells. The hNIS protein, expressed in thyroid cancer, is why most thyroid cancers can be cured or successfully treated with a small dose of (which kills thyroid expressing hNIS). Armed with the ability to force TNBC cells to produce this protein, researchers now have a way to deliver anticancer therapies to this deadly and resistant form of cancer.

"This is an important and significant discovery that basically combines proven cures for two other diseases," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "Even more exciting is that the effects of this virus and radioactive iodine are well known in people, hopefully reducing the amount of time it will take for it to reach the clinic."

More information: Sepideh Gholami, Chun-Hao Chen, Emil Lou, Laurence J. Belin, Sho Fujisawa, Valerie A. Longo, Nanhai G. Chen, Mithat Gönen, Pat B. Zanzonico, Aladar A. Szalay, and Yuman Fong. Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer. FASEB J. February 2014 28:676-682; DOI: 10.1096/fj.13-237222

add to favorites email to friend print save as pdf

Related Stories

Nexavar approval expanded for common thyroid cancer

Nov 24, 2013

(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid ...

Recommended for you

Generation of tanners see spike in deadly melanoma

9 hours ago

(AP)—Stop sunbathing and using indoor tanning beds, the acting U.S. surgeon general warned in a report released Tuesday that cites an alarming 200 percent jump in deadly melanoma cases since 1973.

Penn team makes cancer glow to improve surgical outcomes

9 hours ago

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence.

Cancer: Tumors absorb sugar for mobility

21 hours ago

Cancer cells are gluttons. We have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumor cells are also characterized by a series of features such as mobility or unlikeliness ...

User comments